Amy Vandekop
Vermogen: 3 830 $ op 31-08-2026
Vermogen: 3 830 $ op 31-08-2026
Ms. Amy Vandekop, CPA, is a Chief Accounting Officer & Controller at Kalaris Therapeutics, Inc. Ms. Vandekop was previously employed as a Senior Director-Accounting & Reporting by AlloVir, Inc. and a Senior Manager-Accounting & Reporting by Lumicell, Inc. She received her undergraduate degree from the University of Massachusetts Amherst.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0% | 27-08-2026 | 948 ( 0% ) | 3 830 $ | 31-08-2026 |
| Bedrijven | Functie | Begin |
|---|
| Bedrijven | Functie | Einde |
|---|---|---|
| ALLOVIRPAR | Comptroller/Controller/Auditor | 01-03-2025 |
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Comptroller/Controller/Auditor | 01-12-2020 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 3 |
|---|---|
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Electronic Technology |
AlloVir, Inc.
AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
University of Massachusetts Amherst
University of Massachusetts Amherst Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau